Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
暂无分享,去创建一个
A. Mastroianni | S. Greco | Alfredo Zanolini | Luciana Chidichimo | V. Vangeli | G. De Marco | Filippo Urso | M. Mauro | Francesca Greco
[1] A. Jordan,et al. Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events , 2023, American Journal of Emergency Medicine.
[2] Maja Ortner Hadžiabdić,et al. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry , 2022, Croatian medical journal.
[3] Mohammad Reza Aslani,et al. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients , 2022, Frontiers in Medicine.
[4] Unaiza Naeem,et al. Comparative analysis of neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio with respect to outcomes of in-hospital coronavirus disease 2019 patients: A retrospective study , 2022, Frontiers in Medicine.
[5] Y. Chawla,et al. Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression , 2022, Frontiers in Endocrinology.
[6] M. Hejazi,et al. COVID-19 infection: an overview on cytokine storm and related interventions , 2022, Virology Journal.
[7] M. Hejazi,et al. COVID-19 infection: an overview on cytokine storm and related interventions , 2022, Virology Journal.
[8] Catharine I Paules,et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis , 2022, BMC Infectious Diseases.
[9] Maja Ortner Hadžiabdić,et al. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis , 2022, Journal of Infection.
[10] Yushu Wang,et al. The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis , 2022, Journal of Infection.
[11] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[12] A. Mastroianni,et al. Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis , 2021, International journal of immunopathology and pharmacology.
[13] Š. Manola,et al. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre , 2021, Postgraduate Medical Journal.
[14] Y. Gottwalles,et al. Prognostic Value of C-Reactive Protein to Lymphocyte Ratio (CLR) in Emergency Department Patients with SARS-CoV-2 Infection , 2021, Journal of personalized medicine.
[15] J. Chinen,et al. Secondary immunodeficiencies. An overview. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[16] A. Abbate,et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. , 2021, JAMA.
[17] F. Cipollone,et al. Efficacy of canakinumab in mild or severe COVID‐19 pneumonia , 2021, Immunity, inflammation and disease.
[18] H. Harapan,et al. Antivirals for COVID-19: A critical review , 2020, Clinical Epidemiology and Global Health.
[19] Zhaoyan Feng,et al. Assessment of the Severity of Coronavirus Disease: Quantitative Computed Tomography Parameters versus Semiquantitative Visual Score. , 2020, Korean journal of radiology.
[20] G. Chatellier,et al. Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.
[21] Li Yang,et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage , 2020, Journal of Translational Medicine.
[22] Y. Oda,et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. , 2020, Lung cancer.
[23] M. Metra,et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.
[24] Guiqiang Wang,et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.
[25] E. Ben-Chetrit,et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes , 2018, The New England journal of medicine.
[26] V. Adamo,et al. Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel , 2018, Journal of cellular physiology.
[27] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.